Comprehensive Stock Comparison
Compare Soleno Therapeutics, Inc. (SLNO) vs BioMarin Pharmaceutical Inc. (BMRN) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Value | SLNO | Lower P/E (9.3x vs 15.4x) |
| Quality / Margins | SLNO | 11.0% net margin vs BMRN's 10.8% |
| Stability / Safety | SLNO | Beta 0.68 vs BMRN's 0.74, lower leverage |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | BMRN | -13.3% vs SLNO's -20.0% |
| Efficiency (ROA) | BMRN | 4.6% ROA vs SLNO's 3.7%, ROIC 7.4% vs 15.6% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Soleno Therapeutics is a clinical-stage biopharmaceutical company developing novel treatments for rare diseases. It currently generates no revenue from commercial sales — its financial runway comes from equity financing and potential milestone payments — with its lead candidate in Phase III trials for Prader-Willi syndrome. The company's competitive advantage lies in its focused expertise on rare disease therapeutics and its lead candidate's potential to address a significant unmet medical need in Prader-Willi syndrome.
BioMarin Pharmaceutical is a biotechnology company focused on developing and commercializing therapies for rare genetic diseases. It generates revenue primarily from sales of its orphan drug portfolio — including Voxzogo, Vimizim, and Palynziq — with additional income from licensing and royalties. The company's moat lies in its deep expertise in rare disease biology and its established commercial infrastructure for ultra-orphan drugs, which creates high barriers to entry.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
SLNO leads in 3 of 6 categories (Financial Metrics, Valuation Metrics). BMRN leads in 1 (Total Returns). 1 tied.
Financial Metrics (TTM)
BMRN is the larger business by revenue, generating $3.2B annually — 16.9x SLNO's $190M. Profitability is closely matched — net margins range from 11.0% (SLNO) to 10.8% (BMRN).
| Metric | SLNOSoleno Therapeuti… | BMRNBioMarin Pharmace… |
|---|---|---|
| RevenueTrailing 12 months | $190M | $3.2B |
| EBITDAEarnings before interest/tax | $61M | $613M |
| Net IncomeAfter-tax profit | $21M | $349M |
| Free Cash FlowCash after capex | $47M | $725M |
| Gross MarginGross profit ÷ Revenue | +50.9% | +77.1% |
| Operating MarginEBIT ÷ Revenue | +32.4% | +16.6% |
| Net MarginNet income ÷ Revenue | +11.0% | +10.8% |
| FCF MarginFCF ÷ Revenue | +24.6% | +22.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +17.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +163.0% | -134.4% |
Valuation Metrics
At 34.3x trailing earnings, BMRN trades at a 66% valuation discount to SLNO's 100.2x P/E.
| Metric | SLNOSoleno Therapeuti… | BMRNBioMarin Pharmace… |
|---|---|---|
| Market CapShares × price | $145,692 | $11.9B |
| Enterprise ValueMkt cap + debt − cash | -$67M | $11.1B |
| Trailing P/EPrice ÷ TTM EPS | 100.18x | 34.29x |
| Forward P/EPrice ÷ next-FY EPS est. | 9.28x | 15.45x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | -1.11x | 18.18x |
| Price / SalesMarket cap ÷ Revenue | 0.00x | 3.68x |
| Price / BookPrice ÷ Book value/share | 4.72x | 2.00x |
| Price / FCFMarket cap ÷ FCF | 0.00x | 16.36x |
Profitability & Efficiency
BMRN delivers a 5.7% return on equity — every $100 of shareholder capital generates $6 in annual profit, vs $5 for SLNO. SLNO carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to BMRN's 0.10x. On the Piotroski fundamental quality scale (0–9), SLNO scores 6/9 vs BMRN's 5/9, reflecting solid financial health.
| Metric | SLNOSoleno Therapeuti… | BMRNBioMarin Pharmace… |
|---|---|---|
| ROE (TTM)Return on equity | +4.6% | +5.7% |
| ROA (TTM)Return on assets | +3.7% | +4.6% |
| ROICReturn on invested capital | +15.6% | +7.4% |
| ROCEReturn on capital employed | +15.1% | +7.8% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 5 |
| Debt / EquityFinancial leverage | 0.01x | 0.10x |
| Net DebtTotal debt minus cash | -$67M | -$715M |
| Cash & Equiv.Liquid assets | $70M | $1.3B |
| Total DebtShort + long-term debt | $3M | $597M |
| Interest CoverageEBIT ÷ Interest expense | -6.60x | 48.95x |
Total Returns (with DRIP)
A $10,000 investment in BMRN five years ago would be worth $7,797 today (with dividends reinvested), compared to $1,966 for SLNO. Over the past 12 months, BMRN leads with a -13.3% total return vs SLNO's -20.0%. The 3-year compound annual growth rate (CAGR) favors SLNO at 56.7% vs BMRN's -14.7% — a key indicator of consistent wealth creation.
| Metric | SLNOSoleno Therapeuti… | BMRNBioMarin Pharmace… |
|---|---|---|
| YTD ReturnYear-to-date | -17.2% | +3.8% |
| 1-Year ReturnPast 12 months | -20.0% | -13.3% |
| 3-Year ReturnCumulative with dividends | +284.9% | -38.0% |
| 5-Year ReturnCumulative with dividends | -80.3% | -22.0% |
| 10-Year ReturnCumulative with dividends | -90.9% | -24.6% |
| CAGR (3Y)Annualised 3-year return | +56.7% | -14.7% |
Risk & Volatility
SLNO is the less volatile stock with a 0.68 beta — it tends to amplify market swings less than BMRN's 0.74 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. BMRN currently trades 84.0% from its 52-week high vs SLNO's 43.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | SLNOSoleno Therapeuti… | BMRNBioMarin Pharmace… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.68x | 0.74x |
| 52-Week HighHighest price in past year | $90.32 | $73.51 |
| 52-Week LowLowest price in past year | $32.84 | $50.76 |
| % of 52W HighCurrent price vs 52-week peak | +43.3% | +84.0% |
| RSI (14)Momentum oscillator 0–100 | 41.2 | 56.6 |
| Avg Volume (50D)Average daily shares traded | 1.3M | 1.9M |
Analyst Outlook
Wall Street rates SLNO as "Buy" and BMRN as "Buy". Consensus price targets imply 169.3% upside for SLNO (target: $105) vs 32.8% for BMRN (target: $82).
| Metric | SLNOSoleno Therapeuti… | BMRNBioMarin Pharmace… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $105.20 | $82.00 |
| # AnalystsCovering analysts | 11 | 40 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +100.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Mar 20 | Feb 26 | Change |
|---|---|---|---|
| Soleno Therapeutics… (SLNO) | 100 | 20.37 | -79.6% |
| BioMarin Pharmaceut… (BMRN) | 100 | 61.39 | -38.6% |
BioMarin Pharmaceut… (BMRN) returned -22% over 5 years vs Soleno Therapeutics… (SLNO)'s -80%.
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Soleno Therapeutics… (SLNO) | $1M | $190M | +13024.2% |
| BioMarin Pharmaceut… (BMRN) | $1.1B | $0.00 | -100.0% |
Soleno Therapeutics, Inc.'s revenue grew from $1M (2016) to $190M (2025) — a 71.9% CAGR. BioMarin Pharmaceutical Inc.'s revenue grew from $1.1B (2016) to $0M (2025) — a -100.0% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Soleno Therapeutics… (SLNO) | -8.3% | 11.0% | +231.9% |
| BioMarin Pharmaceut… (BMRN) | -56.4% | 15.0% | +126.5% |
Soleno Therapeutics, Inc.'s net margin went from -8% (2016) to 11% (2025).
Chart 4P/E Ratio History — 5 Years
| Stock | 2020 | 2025 | Change |
|---|---|---|---|
| BioMarin Pharmaceut… (BMRN) | 19.4 | 424.5 | +2088.1% |
BioMarin Pharmaceutical Inc. has traded in a 19x–425x P/E range over 5 years; current trailing P/E is ~34x.
Chart 5EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Soleno Therapeutics… (SLNO) | -58.35 | 0.39 | +100.7% |
| BioMarin Pharmaceut… (BMRN) | -3.79 | 0.14 | +103.7% |
Soleno Therapeutics, Inc.'s EPS grew from $-58.35 (2016) to $0.39 (2025). BioMarin Pharmaceutical Inc.'s EPS grew from $-3.79 (2016) to $0.14 (2025).
Chart 6Free Cash Flow — 5 Years
Soleno Therapeutics, Inc. generated $47M FCF in 2025 (+268% vs 2021). BioMarin Pharmaceutical Inc. generated $725M FCF in 2025 (+291% vs 2021).
SLNO vs BMRN: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is SLNO or BMRN a better buy right now?
BioMarin Pharmaceutical Inc. (BMRN) offers the better valuation at 34.3x trailing P/E (15.4x forward), making it the more compelling value choice. Analysts rate Soleno Therapeutics, Inc. (SLNO) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — SLNO or BMRN?
On trailing P/E, BioMarin Pharmaceutical Inc. (BMRN) is the cheapest at 34.3x versus Soleno Therapeutics, Inc. at 100.2x. On forward P/E, Soleno Therapeutics, Inc. is actually cheaper at 9.3x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — SLNO or BMRN?
Over the past 5 years, BioMarin Pharmaceutical Inc. (BMRN) delivered a total return of -22.0%, compared to -80.3% for Soleno Therapeutics, Inc. (SLNO). A $10,000 investment in BMRN five years ago would be worth approximately $8K today (assuming dividends reinvested). Over 10 years, the gap is even starker: BMRN returned -24.6% versus SLNO's -90.9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — SLNO or BMRN?
By beta (market sensitivity over 5 years), Soleno Therapeutics, Inc. (SLNO) is the lower-risk stock at 0.68β versus BioMarin Pharmaceutical Inc.'s 0.74β — meaning BMRN is approximately 10% more volatile than SLNO relative to the S&P 500. On balance sheet safety, Soleno Therapeutics, Inc. (SLNO) carries a lower debt/equity ratio of 1% versus 10% for BioMarin Pharmaceutical Inc. — giving it more financial flexibility in a downturn.
05Which has better profit margins — SLNO or BMRN?
Soleno Therapeutics, Inc. (SLNO) is the more profitable company, earning 11.0% net margin versus 10.8% for BioMarin Pharmaceutical Inc. — meaning it keeps 11.0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SLNO leads at 32.4% versus 16.6% for BMRN. At the gross margin level — before operating expenses — BMRN leads at 77.1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is SLNO or BMRN more undervalued right now?
On forward earnings alone, Soleno Therapeutics, Inc. (SLNO) trades at 9.3x forward P/E versus 15.4x for BioMarin Pharmaceutical Inc. — 6.2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for SLNO: 169.3% to $105.20.
07Which pays a better dividend — SLNO or BMRN?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is SLNO or BMRN better for a retirement portfolio?
For long-horizon retirement investors, Soleno Therapeutics, Inc. (SLNO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.68)). Both have compounded well over 10 years (SLNO: -90.9%, BMRN: -24.6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between SLNO and BMRN?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.